Who are Rituximab plus CHOP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Venetoclax; Rituximab, Columvi, Lunsumio, Ocrevus, Gazyva, Kesimpta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rituximab-plus-chop.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rituximab plus CHOP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rituximab plus CHOP (Rituximab plus CHOP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody and chemotherapy regimen. Area: Oncology.

phase 3 Monoclonal antibody and chemotherapy regimen CD20 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Rituximab plus CHOP (Rituximab plus CHOP) — Sinocelltech Ltd.. Rituximab targets CD20 on B cells, while CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a chemotherapy regimen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rituximab plus CHOP TARGET	Rituximab plus CHOP	Sinocelltech Ltd.	phase 3	Monoclonal antibody and chemotherapy regimen	CD20
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Columvi	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Kesimpta	OFATUMUMAB	Novartis	marketed	Anti-CD20 monoclonal antibody	CD20	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody and chemotherapy regimen class)

Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rituximab plus CHOP — Competitive Intelligence Brief. https://druglandscape.com/ci/rituximab-plus-chop. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing